Christian Klein

Overview

Best Publications

• In vivo activation of the p53 pathway by small-molecule antagonists of MDM2.

  Lyubomir T. Vassilev;Binh T. Vu;Bradford Graves;Daisy Carvajal

  5457
  Citations

• Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell–mediated B-cell cytotoxicity

  Ekkehard Mössner;Peter Brünker;Samuel Moser;Ursula Püntener

  1314
  Citations

• A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade

  Daniela S. Thommen;Daniela S. Thommen;Viktor H. Koelzer;Petra Herzig;Andreas Roller

  1143
  Citations

• Target Binding Properties and Cellular Activity of Afatinib (BIBW 2992), an Irreversible ErbB Family Blocker.

  Flavio Solca;Goeran Dahl;Andreas Zoephel;Gerd Bader

  1112
  Citations

• Climate change impact and adaptation for wheat protein

  Senthold Asseng;Pierre Martre;Andrea Maiorano;Reimund P Rötter

  543
  Citations

• Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies

  Wolfgang Schaefer;Jörg T. Regula;Monika Bähner;Jürgen Schanzer

  510
  Citations

• Angiopoietin-2 differentially regulates angiogenesis through TIE2 and integrin signaling

  Moritz Felcht;Robert Luck;Alexander Schering;Philipp Seidel

  497
  Citations

• Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties

  Christian Klein;Alfred Lammens;Wolfgang Schäfer;Guy Georges

  413
  Citations

• Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions

  Tilman Schlothauer;Sylvia Herter;Claudia Ferrara Koller;Sandra Grau-Richards

  413
  Citations

• Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab In Vitro and in Xenograft Models

  Sylvia Herter;Frank Herting;Olaf Mundigl;Inja Waldhauer

  408
  Citations

• Progression of Lung Cancer Is Associated with Increased Dysfunction of T Cells Defined by Coexpression of Multiple Inhibitory Receptors

  Daniela Stefanie Thommen;Jens Schreiner;Philipp Müller;Petra Herzig

  406
  Citations

• A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors.

  Marina Bacac;Tanja Fauti;Johannes Sam;Sara Colombetti

  370
  Citations

• Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy.

  Maud Mayoux;Andreas Roller;Vesna Pulko;Stefano Sammicheli

  369
  Citations

• Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53.

  Raphael Stoll;Christian Renner;Silke Hansen;Stefan Palme

  367
  Citations

• Bivalent, bispecific antibodies

  Christian Klein;Wolfgang Schaefer

  360
  Citations

• p53 contains large unstructured regions in its native state.

  Stefan Bell;Christian Klein;Lin Müller;Silke Hansen

  360
  Citations

• Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines.

  Christian Klein;Inja Waldhauer;Valeria G. Nicolini;Anne Freimoser-Grundschober

  334
  Citations

• Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment

  Anja Seckinger;Jose Antonio Delgado;Samuel Moser;Laura Moreno

  324
  Citations

• WT p53, but not tumor-derived mutants, bind to Bcl2 via the DNA binding domain and induce mitochondrial permeabilization.

  York Tomita;Natasha Marchenko;Susan Erster;Alice Nemajerova

  305
  Citations

• Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies

  Christian Klein;Claudio Sustmann;Markus Thomas;Kay Stubenrauch

  298
  Citations